Cel Sci Corp SEC filings CVM
Cel Sci Corp has 1,007 filings in SEC EDGAR's recent list, going back to Jun 12, 2012. Its latest annual report, Form ARS, was filed on Jul 2, 2026 for the period ended Sep 30, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 17, 2026 (shareholder vote results). The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Jul 2, 2026 | Jun 23, 2026 |
| DEF 14A | Proxy statement | Apr 9, 2025 | Mar 31, 2025 |
| PRE 14A | Preliminary proxy statement | Mar 21, 2025 | Mar 12, 2025 |
| DEFA14A | Additional proxy material | Mar 7, 2024 | — |
| DEF 14A | Proxy statement | Mar 7, 2024 | Mar 1, 2024 |
| DEFA14A | Additional proxy material | Apr 10, 2023 | — |
| DEF 14A | Proxy statement | Apr 10, 2023 | May 23, 2023 |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 13, 2022 |
| DEFA14A | Additional proxy material | May 18, 2021 | — |
| DEF 14A | Proxy statement | May 18, 2021 | Jul 1, 2021 |
| DEFA14A | Additional proxy material | Mar 30, 2020 | — |
| DEFA14A | Additional proxy material | Mar 17, 2020 | — |
| DEFA14A | Additional proxy material | Mar 4, 2020 | — |
| DEF 14A | Proxy statement | Mar 4, 2020 | Apr 17, 2020 |
| DEFA14A | Additional proxy material | Mar 28, 2019 | — |
| DEF 14A | Proxy statement | Mar 26, 2019 | May 20, 2019 |
| DEFA14A | Additional proxy material | Aug 8, 2018 | — |
| DEF 14A | Proxy statement | Aug 8, 2018 | Sep 20, 2018 |
| DEFA14A | Additional proxy material | May 11, 2017 | — |
| DEF 14A | Proxy statement | Apr 27, 2017 | Jun 9, 2017 |
| PRE 14A | Preliminary proxy statement | Mar 17, 2017 | May 30, 2017 |
| DEF 14A | Proxy statement | Jun 9, 2016 | Jul 22, 2016 |
| DEF 14A | Proxy statement | Apr 21, 2015 | Apr 14, 2015 |
| PRE 14A | Preliminary proxy statement | Mar 13, 2015 | May 11, 2015 |
| DEFA14A | Additional proxy material | Jul 3, 2014 | — |
| DEF 14A | Proxy statement | May 30, 2014 | Jul 22, 2014 |
| DEFA14A | Additional proxy material | Jun 28, 2013 | — |
| DEFA14A | Additional proxy material | Jun 11, 2013 | — |
| DEF 14A | Proxy statement | May 10, 2013 | Jun 25, 2013 |
| PRE 14A | Preliminary proxy statement | Jan 25, 2013 | Mar 26, 2013 |
Showing 31 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CVM (NYSE)
- Fiscal year ends
- September 30
- Incorporated in
- CO
- Headquarters
- Vienna, VA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 725363
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.